Show Summary Details
Page of

Other and newer antidepressants 

Other and newer antidepressants
Chapter:
Other and newer antidepressants
Author(s):

Basant K. Puri

DOI:
10.1093/med/9780199670444.003.0010
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 21 January 2020

Agomelatine

Duloxetine

Flupentixol

Mirtazapine

Reboxetine

Venlafaxine

Tryptophan

Agomelatine is a new antidepressant with MT1 and MT2 melatonergic agonist and 5-HT2C antagonist actions which has been shown to be effective in severe depression (see Mongomery and Kasper, 2007). These properties, together with its lack of major effects on the uptake of dopamine, serotonin, and noradrenaline, may account for its relative lack of adverse side-effects. As ...

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.